ScreenerHero

COCP Cocrystal Pharma, Inc.

NAS · US · Healthcare · Biotechnology · cocrystalpharma.com
1.060USD-4.50%Mkt Cap: 20.42M $P/E: —

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. The company employs structure-…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$58.08BUSDP/E 35.4
ARGX
argenx SE
$48.23BUSDP/E 31.4
RVMD
Revolution Medicines, Inc.
$43.05BUSD
UCB
UCB SA
$41.82BUSDP/E 17.8
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
GMAB
Genmab A/S
$21.10BUSDP/E 29.1
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap20.42M USD
Enterprise Value20.55M USD
Revenue (TTM)330.00K USD
Gross Profit-5.76M USD
Net Income (TTM)-8.83M USD
Revenue/Share0.03 USD
Last Price1.060 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees10
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.91
PEG—
EV/EBITDA-2.04
EV/Revenue62.29
P/S64.79
P/B14.61
EPS (TTM)-0.76
EPS (Forward)-0.58
52W Range
0.760024% of range2.030
52W High2.030 USD
52W Low0.7600 USD
Profitability
Gross Margin0.00%
Oper. Margin-3032.38%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-139.49%
ROA-90.93%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-8.19M USD
CapEx (TTM)12.00K USD
FCF Margin-1308.71%
FCF Yield-21.15%
Net Debt-828.00K USD
Net Debt/EBITDA0.08
Balance Sheet
Debt/Equity0.24
Current Ratio1.24
Quick Ratio1.11
Book Value/Sh0.08 USD
Cash/Share0.11 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateJan 24, 2018
Splits
Last Split1:12
Split DateOct 11, 2022
Analyst Consensus
Rating—
Target (Mean)9.000 USD
Upside (mean)+749.1%
Target Range8.000 USD – 10.00 USD
8.000+749.1% to mean10.00
# Analysts2
Ownership
Shares Out.19.26M
Float11.91M
Insiders65.71%
Institutions5.77%
Short Interest
Short Ratio5.7d
Short % Float2.04%
Short % Out.1.68%
Shares Short322.75K
Short (prev mo.)307.61K
Technical
SMA 501.107 (-4.2%)
SMA 2001.104 (-4.0%)
Beta1.48
S&P 52W Chg16.45%
Avg Vol (30d)49.83K
Avg Vol (10d)44.51K
Technical Indicators
RSI (14)40.3
MACD-0.0017
MACD Signal0.0153
MACD Hist.-0.0170
BB Upper1.262 USD
BB Middle1.167 USD
BB Lower1.072 USD
BB Width16.26%
ATR (14)0.0685 USD
Vol Ratio (20d)0.55x